Equasens — Cyborg Score 7/10

Strong
Healthcare Information Technology & Software Solutions

Strategic Profile

The company's growth strategy focuses on supporting healthcare professionals across primary care and hospital settings with software, hardware, financing and data-hosting solutions, with recent complementary acquisitions in digital training generating operational synergies. The company maintains strong geographic concentration with 87.9% of revenue from France, and selective expansion into Italy (5.7%), Belgium (3%), Germany (2.4%) and other European markets.

Cyborg Score Rationale

Equasens demonstrates solid market positioning as France's leading healthcare software provider with consistent revenue growth (9.1% in 2025), strong recurring revenue (ARR €108M), and strategic M&A initiatives in high-growth areas like digital training. However, the company faces geographic concentration risk with 88% of revenue from France and operates in a competitive healthcare IT segment.

Top Insights

  • Acquisition of 80% controlling stake in Erevo (announced January 2026), a leading digital training provider for healthcare professionals founded in 2018, expanding portfolio beyond software into continuing education
  • FY2025 revenue of €236.5M with 9.1% growth in reported figures, demonstrating consistent organic expansion
  • Diversified revenue streams: 75.4% from pharmacy software, 14.8% from healthcare facility IT solutions, and 9.8% from e-Health and telemedicine infrastructure
  • Comprehensive support ecosystem including electronic equipment, digital solutions, healthcare robotics, data hosting, financing and training services

Named Competitors

  • Healthcare IT Software — International healthcare IT and EHR providers
  • Pharmacy Management Software — Global and regional pharmacy IT solutions
  • Regional Healthcare Software — Fragmented local and national healthcare software vendors

Recent Developments

  • (January 2026) Acquisition of 80% stake in Erevo, digital training pure-play for healthcare professionals
  • (December 2025) Strong H2 2025 performance with ARR of €108M (+8.8%) and annual revenue of €236.5M (+9.1%)
  • (2024) Acquisitions of DIGIPHARMACIE (70% stake) and CALIMED (90% stake) to strengthen pharmacy digitization and private practice software offerings

Open the full interactive Equasens report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →